Promising Practices Promising PracticesPromising Practices
A forum for government's best ideas and most innovative leaders.

Scientists Make Progress in Slowing Diabetes

ARCHIVES
Image via Andrey_Popov/Shutterstock.com

Type 2 diabetes (T2D) has arguably reached epidemic levels in this country; between 22 and 24 million people suffer from the disease. But now there’s an exciting new development: scientists at the Harvard Stem Cell Institute have discovered a hormone that might slow or stop the progression of diabetes.

T2D is the most common type of diabetes, accounting for about 95% of cases. The hallmark is high blood sugar. It is linked to obesity, which increases the body’s demand for more and more insulin. T2D develops when specific insulin-producing cells in the pancreas, called beta cells, become exhausted and can’t keep up with the increased demand. With insufficient insulin, blood glucose levels rise. Over time, these high levels of glucose can lead to heart disease, stroke, blindness, kidney disease, nerve damage, and even amputations. T2D can be helped by weight loss and exercise, but often oral medication or insulin shots are ultimately needed.

Treating diabetes costs the U.S. a veritable fortune. Last year the bill came to $245 billion—that’s $176 billion in direct medical costs and another $69 billion in lower productivity. We need a game changer. The new discovery just might lead to that, though it won’t happen overnight.

The NIH-funded researchers set out to try to identify a signal that seems to be sent by the liver to the beta cells when the insulin receptor is blocked and blood glucose levels rise.  The researchers found that after the insulin receptor was blocked, one particular liver gene increased its activity rather dramatically. They were able to show that this gene, which turned out to be one of the 20,000 genes that hasn’t attracted much attention so far, coded for a secreted protein. Because it helps beta cells grow, they named it “betatrophin.” This work was done in the mouse, but there’s an almost identical counterpart in the human. When the researchers engineered normal healthy mice to manufacture more of the hormone in their livers, the pancreas responded and made more insulin-producing beta cells.

Betatrophin sends the beta cells into a frenzy causing them to replicate as much as 30 times their normal rate! No other chemical or natural protein has ever caused such a dramatic boost in beta cell proliferation.

It’s not every day that a new and important hormone is discovered! But betatrophin has an important normal role in maintaining normal glucose levels. The amount of betatrophin produced in the liver (and in fat cells) rises naturally whenever the body needs to expand its inventory of beta cells: for example, during pregnancy, when the mother’s body needs to make more beta cells to accommodate the demands of the fetus.

The next step will be to see whether these extra beta cells, produced by administration of betatrophin, can produce enough insulin to halt and possibly reverse the disease in sick diabetic mice. If all goes well, we could be testing betatrophin in humans within two or three years.

Betatrophin could also help treat type 1 diabetes, which develops because the immune system attacks and destroys the insulin-producing beta cells in the pancreas. Currently, the only treatment for type 1 diabetes is insulin shots. But the researchers suspect that betatrophin might work during a critical time called the “honeymoon” period, which is a short window after the onset of disease but before all the patients’ beta cells have been wiped out.

In the future, rather than taking three insulin shots every day to treat their disease, people with T2D might receive a weekly or monthly betatrophin injection to produce more beta cells and keep their blood sugar at a healthy level. That would be a true paradigm shift in the treatment of this disease.

Image via Andrey_Popov/Shutterstock.com

Francis S. Collins, M.D., Ph.D. is the Director of the National Institutes of Health (NIH). In that role he oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at the NIH from 1993-2008.

FROM OUR SPONSORS
JOIN THE DISCUSSION
Close [ x ] More from GovExec
 
 

Thank you for subscribing to newsletters from GovExec.com.
We think these reports might interest you:

  • Sponsored by G Suite

    Cross-Agency Teamwork, Anytime and Anywhere

    Dan McCrae, director of IT service delivery division, National Oceanic and Atmospheric Administration (NOAA)

    Download
  • Data-Centric Security vs. Database-Level Security

    Database-level encryption had its origins in the 1990s and early 2000s in response to very basic risks which largely revolved around the theft of servers, backup tapes and other physical-layer assets. As noted in Verizon’s 2014, Data Breach Investigations Report (DBIR)1, threats today are far more advanced and dangerous.

    Download
  • Sponsored by One Identity

    One Nation Under Guard: Securing User Identities Across State and Local Government

    In 2016, the government can expect even more sophisticated threats on the horizon, making it all the more imperative that agencies enforce proper identity and access management (IAM) practices. In order to better measure the current state of IAM at the state and local level, Government Business Council (GBC) conducted an in-depth research study of state and local employees.

    Download
  • Sponsored by Aquilent

    The Next Federal Evolution of Cloud

    This GBC report explains the evolution of cloud computing in federal government, and provides an outlook for the future of the cloud in government IT.

    Download
  • Sponsored by LTC Partners, administrators of the Federal Long Term Care Insurance Program

    Approaching the Brink of Federal Retirement

    Approximately 10,000 baby boomers are reaching retirement age per day, and a growing number of federal employees are preparing themselves for the next chapter of their lives. Learn how to tackle the challenges that today's workforce faces in laying the groundwork for a smooth and secure retirement.

    Download
  • Sponsored by Hewlett Packard Enterprise

    Cyber Defense 101: Arming the Next Generation of Government Employees

    Read this issue brief to learn about the sector's most potent challenges in the new cyber landscape and how government organizations are building a robust, threat-aware infrastructure

    Download
  • Sponsored by Aquilent

    GBC Issue Brief: Cultivating Digital Services in the Federal Landscape

    Read this GBC issue brief to learn more about the current state of digital services in the government, and how key players are pushing enhancements towards a user-centric approach.

    Download

When you download a report, your information may be shared with the underwriters of that document.